Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rezetamig, an antibody targeting CD3 × CD22.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opelkibart, an antibody targeting KIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Linclatamig, an antibody targeting LY6G6D × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enristomig, an antibody targeting PD-L1 × 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Donitabart, an antibody targeting Ganglioside GD2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denikitug, an antibody targeting CCR8.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Azirkitug, an antibody targeting CCR8.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alextatug, an antibody targeting RNP complex containing PABPC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Stamulumab, an antibody targeting MSTN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Milatuzumab, an antibody targeting CD74.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lumretuzumab, an antibody targeting HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Elgemtumab, an antibody targeting HER3.